๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of NK313 in malignant lymphomas: an NK313 Malignant Lymphoma Study Group trial

โœ Scribed by Takashi Yoshida; Makoto Ogawa; Kazuo Ota; Yutaka Yoshida; Akira Wakui; Masao Oguro; Yutaka Ariyoshi; Masami Hirano; Ikurou Kimura; Tamotsu Matsuda

Publisher
Springer
Year
1993
Tongue
English
Weight
392 KB
Volume
31
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II trial of cis-dichlorodiamminepl
Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B
โœ F. Cavalli; Dr. W. F. Jungi; N. I. Nissen; T. F. Pajak; M. Coleman; J. F. Hollan ๐Ÿ“‚ Article ๐Ÿ“… 1981 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 279 KB ๐Ÿ‘ 3 views

In a cooperative study of the Cancer and Acute Leukemia Group B, 27 evaluable patients with advanced malignant lymphomas were treated with 70 mg/m2 of cisdichlorodiammineplatinum(l1) (cis-platinum) once every three weeks. All patients had received extensive prior therapy. Partial remission was obtai

Phase II trial of PCNU in advanced malig
Phase II trial of PCNU in advanced malignant melanoma: an Eastern Cooperative Oncology Group pilot study
โœ Robert H. Earhart; Franco M. Muggia; Frederick M. Golomb ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› Springer US ๐ŸŒ English โš– 327 KB

PCNU, a chloroethylnitrosourea with high alkylating activity, low carbamoylating activity, optimal octanol: water partition coefficient and broad activity in animal systems, was administered to 32 evaluable patients with measurable metastatic melanoma by brief intravenous infusions every six weeks.

Phase II study of trimetrexate in malign
Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study
โœ Neill A. Iscoe; Elizabeth A. Eisenhauer; Audley J. Bodurtha ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› Springer US ๐ŸŒ English โš– 183 KB

The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxic

Ifosfamide/Carboplatin/Etoposide (ICE),
Ifosfamide/Carboplatin/Etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: A Pediatric Oncology Group phase II study
โœ Kung, Faith H.; Harris, Michael B.; Krischer, Jeffrey P. ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 41 KB ๐Ÿ‘ 2 views

nary observations on ICE as salvaging therapy for refractory NHL are encouraging. More study is needed to confirm our findings and to delineate which subtypes of NHL are most responsive to ICE therapy.